research Vogt-Koyanagi-Harada Disease Occurring During Pegylated Interferon-α2b and Ribavirin Combination Therapy for Chronic Hepatitis C
Vogt-Koyanagi-Harada disease can develop during interferon therapy for chronic hepatitis C.
Search
for
Sort by
Research
30 / 1000+ results 
research Alopecia Universalis After Discontinuation of Pegylated Interferon and Ribavirin Combination Therapy for Hepatitis C: A Case Report
A man lost all his hair after stopping hepatitis C treatment and it didn't grow back.
research Exacerbation of Alopecia Areata During Pegylated Interferon Alpha-2b and Ribavirin Therapy, Possibly Due to the Collapse of Hair Follicle Immune Privilege
A woman's hair loss worsened after starting hepatitis C treatment due to immune changes in her hair follicles.
research Multiple Sclerosis: Side Effects of Interferon Beta Therapy and Their Management
The article suggests managing interferon beta therapy side effects in MS with dose adjustments, medications, and patient education.
research Reversible Alopecia Universalis During Treatment with PEG-Interferon and Ribavirin for Chronic Hepatitis C
Some patients may experience temporary total hair loss from hepatitis C treatment with PEG-interferon and ribavirin.
research Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
A comprehensive approach to educating patients and managing side effects is crucial for improving adherence to multiple sclerosis treatments and patient quality of life.
research Straight Hair Associated with Interferon-Alpha Plus Ribavirin in Hepatitis C Infection
ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.
research Interferon Alfa-2a in the Treatment of Cutaneous T Cell Lymphoma
Interferon alfa-2a is effective for treating cutaneous T cell lymphoma but has significant side effects.
research A Review of Adverse Cutaneous Drug Reactions Resulting from the Use of Interferon and Ribavirin
Interferon and ribavirin can cause serious skin reactions and other health issues.
research Segmental Vitiligo and Hair Curling After Interferon Alpha and Ribavirin Treatment for Hepatitis C
A woman developed white patches on her skin and curly hair after hepatitis C treatment, likely due to the medication interferon alpha.
research Irreversible Alopecia Universalis During Treatment With Pegylated Interferon-Ribavirin for Chronic Hepatitis C Virus Infection: Case Report and Literature Review
A man lost all his hair permanently after hepatitis C treatment, a side effect not seen before.
research Excessive Hair Growth Around Local Beta-Interferon Injection Sites for Malignant Melanoma
β-interferon injections for melanoma can cause excessive hair growth at the injection sites.
research Cutaneous Reactions to Recombinant Cytokine Therapy
Recombinant cytokine therapy can cause skin reactions ranging from mild to severe.
research Telogen Effluvium Due to Recombinant Interferon Alpha-2b
Half of the patients treated with a specific drug for skin cancer experienced hair loss not related to the drug's dosage.
research Pegylated-Interferon-Alpha 2a in Clinical Practice: How to Manage Patients Suffering from Side Effects
Manage side effects of hepatitis C treatment with dose changes and medications, which may improve patient adherence and treatment success.
research Alopecia Areata After Hepatitis C Virus Infection Treatment: A Case Report
A patient developed hair loss after hepatitis C treatment with sofosbuvir and ribavirin.
research Zinc: A Complementary Factor in the Treatment of Chronic Hepatitis C?
Zinc supplementation may help improve treatment outcomes for chronic hepatitis C.
research Hepatitis C Treatment and Alopecia Totalis
Hepatitis C treatment may trigger complete hair loss, especially in those with a history of patchy hair loss, but hair usually grows back within a year.
research Medical Therapies
Combination therapies might work better for some vitiligo patients, but results vary.
research Interferon in the Treatment of Cutaneous T-Cell Lymphoma
Interferon, especially alfa interferon, is an effective treatment for cutaneous T-cell lymphoma with manageable side effects.
research Cutaneous Ulcers Due to Interferon Seem Not to Be Related to the Dosage
Skin ulcers from interferon may not depend on the amount given.
research A Prospective Study of Cutaneous Adverse Events Induced by Low-Dose Alpha-Interferon Treatment for Malignant Melanoma
Most patients treated with low-dose alpha-interferon for malignant melanoma experienced skin side effects, with hair loss being the most frequent.
research Lichen Planus and Other Cutaneous Manifestations in Chronic Hepatitis C: Pre- and Post-Interferon-Based Treatment Prevalence in a Cohort from a Low Hepatitis C Virus Endemic Area
Skin problems like itching, dry skin, and hair loss are more common in hepatitis C patients after interferon treatment, but lichen planus is not linked to the infection.
research Adverse Cutaneous Reactions to Chemotherapeutic Agents and Cytokine Therapy
Chemotherapy and cytokine therapy can cause various skin reactions, including hair loss and hypersensitivity.
research Skin Complications Associated With Interferon-Beta Treatment In Patients With Multiple Sclerosis, Tehran In 2021
Interferon beta treatment in MS patients can cause skin reactions and increased hair loss.
research The Influence of Interferon on Healthy and Diseased Skin
Type I interferons play a key role in the development of various skin diseases.
research Alopecia Associated with Fluconazole Therapy
High doses of fluconazole can cause reversible hair loss.
research Alopecia Universalis Following Interferon Alfa-2b and Ribavirin Treatment for Hepatitis C
A woman lost all her body hair after hepatitis C treatment, but it started to grow back a year after stopping the treatment.
research Interferons in Dermatology
Interferons are effective for some skin conditions and cancers, but can have side effects and need more research for optimal use.
research Multiple Sclerosis Disease-Modifying Therapies: Adverse Effect Surveillance and Management
The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.